Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non Operating Income: 2022-2025

Historic Other Non Operating Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $292,000.

  • Taysha Gene Therapies' Other Non Operating Income rose 460.49% to $292,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $286,000, marking a year-over-year increase of 100.44%. This contributed to the annual value of -$110,000 for FY2024, which is 100.32% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Other Non Operating Income of $292,000 as of Q3 2025, which was up 6.96% from $273,000 recorded in Q2 2025.
  • Taysha Gene Therapies' Other Non Operating Income's 5-year high stood at $100.5 million during Q3 2023, with a 5-year trough of -$65.7 million in Q4 2023.
  • Its 3-year average for Other Non Operating Income is $3.2 million, with a median of -$8,000 in 2023.
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Other Non Operating Income showed a top increase of 10,045,700.00% in 2023 and a maximum decrease of 1,095,533.33% in 2023.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Other Non Operating Income stood at -$6,000 in 2022, then tumbled by 1,095,533.33% to -$65.7 million in 2023, then skyrocketed by 99.73% to -$177,000 in 2024, then surged by 460.49% to $292,000 in 2025.
  • Its last three reported values are $292,000 in Q3 2025, $273,000 for Q2 2025, and -$102,000 during Q1 2025.